News

$5 million Fox Foundation grant targets GBA1 Parkinson’s research

The Michael J. Fox Foundation for Parkinson’s Research (MJFF) has awarded a $5 million grant to Congruence Therapeutics to advance the development of small molecules for Parkinson’s disease associated with mutations in the GBA1 gene. The research grant will support the optimization and clinical development of therapeutic candidates…

AI speech analysis detects subtle signs of Parkinson’s

Scientists at the University of Rochester have developed an artificial intelligence (AI)-powered screening tool that analyzes a person’s speech patterns to detect subtle signs of Parkinson’s disease. The algorithm could eventually be used to analyze speech patterns at home on mobile phones or household devices, helping to reach people…

Stem cell therapy eases Parkinson’s motor symptoms in trial

S.Biomedics said its stem cell-based therapy A9-DPC was found safe and effective in improving motor function over a one-year follow-up in people with Parkinson’s disease. The results apply to all 12 adults diagnosed with Parkinson’s for at least five years, who were treated with a single brain transplant…

Canada considers approval of Parkinson’s therapy Crexont

Health Canada will review Knight Therapeutics’ application seeking approval of Crexont, an extended-release formulation of levodopa and carbidopa aimed at providing steady symptom control in Parkinson’s disease, the company said. The Parkinson’s therapy is designed to maintain consistent levels of levodopa and carbidopa in the body, prolonging…

Dogs can smell Parkinson’s signature on skin: Study

Two trained dogs detected Parkinson’s disease with high accuracy by smelling skin swabs of patients who had not yet received treatment, adding to growing evidence that scent carries a chemical signature that could help enable early, noninvasive diagnosis. Bumper, a golden retriever, and Peanut, a black Labrador, were trained…